HR 3715

Personal Drug Importation Fairness Act of 2013

Congress: 113 (2013–2015, Ended)
Chamber: House
Policy Area: Health
Introduced: Dec 12, 2013
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Dec 13, 2013)
Official Text: https://www.congress.gov/bill/113th-congress/house-bill/3715

Sponsor

Name: Rep. Ellison, Keith [D-MN-5]
Party: Democratic • **State:** MN • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Rohrabacher, Dana [R-CA-48]	R · CA		Dec 12, 2013
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Dec 19, 2013

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 13, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 12, 2013)

Personal Drug Importation Fairness Act of 2013 - Allows a drug to be imported into the United States, and re-imported into the United States by a person other than the drug's manufacturer, if the drug: (1) has the same active ingredients, route of administration, and strength as a prescription drug approved under provisions of the Federal Food, Drug, and Cosmetic Act (FFDCA) regarding adulterated drugs; (2) may be lawfully marketed in, and is imported or reimported from, a qualified country; (3) is dispensed by a licensed pharmacist; (4) is shipped directly to, or is imported by, the ultimate consumer from the qualified country; (5) is shipped or imported in quantities that do not exceed a 90-day supply; and (6) is accompanied by a copy of a valid prescription.

Defines: (1) "drug" for purposes of this Act as excluding any controlled substance; and (2) "qualified country" to mean any of specified countries (Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, a member-state of the European Union, or a country in the European Economic Area) that is determined by the Commissioner of Food and Drugs (FDA) to have standards for ensuring drug safety and effectiveness that are at least as protective as U.S. standards.

Actions Timeline

- **Dec 13, 2013:** Referred to the Subcommittee on Health.
- **Dec 12, 2013:** Introduced in House
- **Dec 12, 2013:** Referred to the House Committee on Energy and Commerce.